Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

11,12-Epoxyecosatrienoic acids mitigate endothelial dysfunction associated with estrogen loss and aging: Role of membrane depolarization.

Sun C, Simon SI, Foster GA, Radecke CE, Hwang HV, Zhang X, Hammock BD, Chiamvimonvat N, Knowlton AA.

J Mol Cell Cardiol. 2016 May;94:180-8. doi: 10.1016/j.yjmcc.2016.03.019.

PMID:
27079253
2.

Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Spector AA, Kim HY.

Biochim Biophys Acta. 2015 Apr;1851(4):356-65. doi: 10.1016/j.bbalip.2014.07.020. Review.

3.

Epoxyeicosatrienoic acids and cardioprotection: the road to translation.

Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM.

J Mol Cell Cardiol. 2014 Sep;74:199-208. doi: 10.1016/j.yjmcc.2014.05.016. Review.

4.

Epoxyeicosatrienoic acids protect cardiac cells during starvation by modulating an autophagic response.

Samokhvalov V, Alsaleh N, El-Sikhry HE, Jamieson KL, Chen CB, Lopaschuk DG, Carter C, Light PE, Manne R, Falck JR, Seubert JM.

Cell Death Dis. 2013 Oct 24;4:e885. doi: 10.1038/cddis.2013.418.

5.

CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy.

Westphal C, Spallek B, Konkel A, Marko L, Qadri F, DeGraff LM, Schubert C, Bradbury JA, Regitz-Zagrosek V, Falck JR, Zeldin DC, Müller DN, Schunck WH, Fischer R.

PLoS One. 2013 Aug 30;8(8):e73490. doi: 10.1371/journal.pone.0073490.

6.

Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat.

Hye Khan MA, Neckár J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, Falck JR, Imig JD.

Hypertension. 2013 Nov;62(5):905-13. doi: 10.1161/HYPERTENSIONAHA.113.01949.

7.

Diminished acyl-CoA synthetase isoform 4 activity in INS 832/13 cells reduces cellular epoxyeicosatrienoic acid levels and results in impaired glucose-stimulated insulin secretion.

Klett EL, Chen S, Edin ML, Li LO, Ilkayeva O, Zeldin DC, Newgard CB, Coleman RA.

J Biol Chem. 2013 Jul 26;288(30):21618-29. doi: 10.1074/jbc.M113.481077.

8.

Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.

Khan MA, Liu J, Kumar G, Skapek SX, Falck JR, Imig JD.

FASEB J. 2013 Aug;27(8):2946-56. doi: 10.1096/fj.12-218040. Erratum in: FASEB J. 2014 Jan;28(1):520.

10.

Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolase.

Kim IH, Nishi K, Kasagami T, Morisseau C, Liu JY, Tsai HJ, Hammock BD.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5889-92. doi: 10.1016/j.bmcl.2012.07.074.

11.

Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.

Guglielmino K, Jackson K, Harris TR, Vu V, Dong H, Dutrow G, Evans JE, Graham J, Cummings BP, Havel PJ, Chiamvimonvat N, Despa S, Hammock BD, Despa F.

Am J Physiol Heart Circ Physiol. 2012 Oct 1;303(7):H853-62. doi: 10.1152/ajpheart.00154.2012.

12.

Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.

Neckář J, Kopkan L, Husková Z, Kolář F, Papoušek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Malý J, Netuka I, Ošťádal B, Červenka L.

Clin Sci (Lond). 2012 Jun;122(11):513-25. doi: 10.1042/CS20110622.

13.

Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Imig JD.

Physiol Rev. 2012 Jan;92(1):101-30. doi: 10.1152/physrev.00021.2011. Review.

14.

Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice.

Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, Zeldin DC.

J Clin Invest. 2012 Jan;122(1):178-91. doi: 10.1172/JCI58128.

15.

Differential effect of amyloid β on the cytochrome P450 epoxygenase activity in rat brain.

Sarkar P, Narayanan J, Harder DR.

Neuroscience. 2011 Oct 27;194:241-9. doi: 10.1016/j.neuroscience.2011.07.058.

16.

Abdominal surgical incision induces remote preconditioning of trauma (RPCT) via activation of bradykinin receptors (BK2R) and the cytochrome P450 epoxygenase pathway in canine hearts.

Gross GJ, Baker JE, Moore J, Falck JR, Nithipatikom K.

Cardiovasc Drugs Ther. 2011 Dec;25(6):517-22. doi: 10.1007/s10557-011-6321-9.

17.

20-Iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15-epoxyeicosatrienoic acid receptor.

Chen Y, Falck JR, Manthati VL, Jat JL, Campbell WB.

Biochemistry. 2011 May 10;50(18):3840-8. doi: 10.1021/bi102070w.

18.

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions.

Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR.

Front Physiol. 2010 Dec 3;1:157. doi: 10.3389/fphys.2010.00157.

19.

Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease.

Li N, Liu JY, Qiu H, Harris TR, Sirish P, Hammock BD, Chiamvimonvat N.

Congest Heart Fail. 2011 Jan-Feb;17(1):42-6. doi: 10.1111/j.1751-7133.2010.00209.x. Review. No abstract available.

20.

14,15-Dihydroxy-eicosa-5(Z)-enoic acid selectively inhibits 14,15-epoxyeicosatrienoic acid-induced relaxations in bovine coronary arteries.

Bukhari IA, Gauthier KM, Jagadeesh SG, Sangras B, Falck JR, Campbell WB.

J Pharmacol Exp Ther. 2011 Jan;336(1):47-55. doi: 10.1124/jpet.110.169797.

Items per page

Supplemental Content

Support Center